He is the director of the immune radiation program at MD Anderson, with the goal of using radiation to turn the tumor into an “in-situ” vaccine to prime T cells, turning radiation into a systemic therapy. Being able to both see patients and run a lab has provided Dr. Welsh insights into how to improve patient care. His lab recently developed the first mouse model of PD1 resistance and actively investigates the mechanisms how cancer cells adapt to evade the immune system.